|
|
Article: Samaritan Reports Positive Preliminary Results with ''Oral'' HIV Entry Inhibitor in Phase II 10-Day HIV Monotherapy Trial.
- Article from:
- Business Wire
- Article date:
- May 30, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LAS VEGAS -- Samaritan Pharmaceuticals Inc. (AMEX:LIV):
--Data Shows 0.4 log10 Difference Between the High-Dose and the Placebo Control Group
--Dose dependent relationship in the number of subjects who had a reduction in viral load with the high dose group showing the most difference as compared to placebo (55% SP-01A vs. 0% placebo)
Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today, its preliminary results showing antiviral activity in only 10 days with its Phase II 10-Day Monotherapy study where SP-01A, an oral entry inhibitor, was tested "alone" in patients experiencing HIV drug resistance.
...